Highest-materiality recent filing
Avalo Therapeutics expands pipeline with AVTX-010, a long-acting anti-IL-1β mAb; IND planned H1 2027
AVTX-010 is an engineered anti-IL-1β mAb for hidradenitis suppurativa and other inflammatory disorders.
Avalo exchanges Series C shares to lift beneficial ownership cap; revises exec severance
Exchanged 4,294.675 Series C shares for new Series C-1 shares, removing restriction that capped beneficial ownership at 4.99% (now 9.99%).
Avalo reports Q1 net loss $19.6M, Phase 2 HS trial meets endpoints, $431M offering
Phase 2 LOTUS topline: HiSCR75 absolute improvement 42.2% (150mg) and 42.9% (300mg) vs placebo 25.6%; p=0.018 and 0.015.
Avalo Therapeutics raises ~$405M in public offering; preliminary cash $82M as of March 31
Offering of 19.73M shares at $17.75/share plus 1.4M pre-funded warrants at $17.749/warrant.
Abdakibart 150 mg achieved 42.2% HiSCR75 (p=0.018), 300 mg achieved 42.9% (p=0.015); placebo 25.6%.
Avalo Therapeutics reports 2025 net loss of $78.3M; Phase 2 HS topline data due Q2 2026
Net loss $78.3M ($5.84 per share) vs $35.1M in 2024; operating expenses rose to $73M.
Avalo Therapeutics estimates $98M cash as of Dec 31, 2025 in preliminary update
Preliminary cash, cash equivalents and short-term investments of ~$98M as of December 31, 2025.
Avalo Therapeutics Q3 net loss $30.6M; completes Phase 2 LOTUS enrollment for AVTX-009
Completed enrollment in Phase 2 LOTUS trial (~250 adults) for AVTX-009 in hidradenitis suppurativa; topline data expected mid-2026.
Avalo completes Phase 2 LOTUS enrollment for AVTX-009; topline data mid-2026
Enrolled ~250 patients, exceeding the 222-patient target.
Avalo Therapeutics appoints Kevin Lind to Board effective Oct 1; Dr. Almenoff resigns
Kevin Lind appointed to Board effective Oct 1, 2025; will serve on Audit Committee and receive option for 40,200 shares vesting over 3 years.
Avalo Q2 2025 net loss $20.8M; cash $113.3M; Phase 2 LOTUS >75% enrolled, topline mid-2026
Net loss of $20.8M in Q2 2025 ($1.92 per share) compared to net income of $98.5M ($4.21 basic EPS) in Q2 2024, driven by warrant-related items.
Entered Sales Agreement with TD Cowen for at-the-market offering of up to $75M in common stock.
Avalo Q1 net loss $13.1M; cash $125M; Phase 2 HS data expected 2026
Net loss $13.1M ($1.25/shr) vs $121.3M in Q1 2024; prior-year included warrant and acquisition charges.
Avalo reports 2024 net loss of $35.1M; cash of $134.5M funds into at least 2027
Cash and equivalents $134.5M at Dec 31, 2024 vs $7.4M in 2023; runway into at least 2027.
Avalo receives $69.4M from full warrant exercise; cash runway into at least 2027
Gross proceeds of $69.4M from exercise of 11,967,526 warrants at $5.796933/share; total private placement proceeds now $185M.
Avalo Q3 net income $23M; first patient dosed in Phase 2 LOTUS trial for HS
Net income of $23.0M for Q3 2024 vs net loss of $5.2M in Q3 2023; diluted net loss per share $2.83.
Avalo doses first patient in Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa
Phase 2 LOTUS trial enrolling ~180 adults with moderate to severe hidradenitis suppurativa.
Cash and cash equivalents $93.4M as of June 30, 2024; expected cash runway into 2027.
Nasdaq grants Avalo Therapeutics 180-day extension to regain equity compliance
Reported stockholders' equity of negative $112.5M as of March 31, 2024, falling short of Nasdaq's $2.5M minimum.
Avalo Therapeutics appoints Mittie Doyle, M.D., as CMO; grants 234,000-share option
Dr. Doyle, former CMO at Aro Biotherapeutics, brings over 20 years of pharma/biotech experience.
FDA cleared IND for AVTX-009 (anti-IL-1β mAb) allowing Phase 2 LOTUS trial in moderate-to-severe HS.
AlmataBio net loss of $659k from inception (April 28, 2023) to Dec 31, 2023; cash $1.8M, total assets $1.8M.
Avalo Therapeutics receives Nasdaq delisting notice for negative stockholders' equity of $112.6M
Reported stockholders' equity of negative $112.6M in Q1 2024 10-Q, below $2.5M minimum.
Avalo Q1 net loss $121.3M driven by warrant fair value charge; cash $110M into 2027
Cash and cash equivalents $110.2M at March 31, 2024; expects runway through AVTX-009 Phase 2 data readout and into 2027.
Avalo acquires AVTX-009 anti-IL-1β mAb, closes $115.6M private placement; 2023 net loss $31.5M
Acquired AVTX-009 (anti-IL-1β mAb) via acquisition of AlmataBio for $15M in stock plus $7.5M at close; milestones up to $20M.
Avalo acquires Phase 2-ready anti-IL-1β mAb via merger with AlmataBio, raises $115.6M PIPE
Acquired AlmataBio for ~$15M in stock (171,605 common shares + 2,412 Series C Preferred), plus up to $27.5M in milestones.
On June 17, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Rita Jain, M.D. to the Board, effective immediately.
On March 25, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Michael Heffernan to the Board, effective immediately.
On January 2, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025.
On July 16, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Mittie Doyle, M.D., FACR, as Chief Medical Officer, effective July 15, 2024.
On June 24, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Paul Varki as Chief Legal Officer of the Company.
the Company increased the size of the Board to nine members and appointed each of Aaron Kantoff and Samantha Truex, effective as of the closing of the Private Placement, estimated to be on March 28, 2024
Jonathan Goldman was appointed to the Board.
the Company increased the size of the Board to nine members and appointed each of Aaron Kantoff and Samantha Truex, effective as of the closing of the Private Placement, estimated to be on March 28, 2024
The Board appointed the Company’s President and Chief Executive Officer and Board member, Dr. Garry Neil, M.D., to replace Mr. Boyd as Chairman of the Board.
On August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) that they have resigned from their positions on the Board.
On August 8, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) that they have resigned from their positions on the Board.
On February 14, 2022, the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Garry A. Neil as President and Chief Executive Officer of the Company and Christopher Sullivan as Chief Financial Officer, effective February 14, 2022.
Max materiality 0.90 · Median 0.60 · Most common event other_material